Actually schedule G is structured to eliminate randomness so that it instructs the minister to focus on certain things when scheduling.
Right now many companies can fit their filings in either the device side or the drug side, but more and more as you're seeing different manufacturing models, technology like artificial intelligence, it would require a regulatory change to really get right through the pathway. So, really the advantage of this is to lift it away from the device regulations, the drug regulations, and put it in a place where we can rapidly tailor the requirements.
It's not just for any product. It's really to make sure that this is for advanced scientific products. It's for products that don't fit in the regulations right now and that would be suitable to be governed in this particular way. There is a lot of deliberation on what the criteria would be, looking at the advancement of the science and technology, the level of uncertainty around the benefits and potential harms. For things like wearables, for example, we're all figuring out how to regulate those. Giving a licence for each one may not be possible. This actually creates a schedule in an orderly way that we list the products to go into that space.
Once we know more about regulating it, we may bring it back over to the normal regulations once we understand how to normalize that.